X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ipilimumab (121) 121
index medicus (99) 99
oncology (96) 96
humans (89) 89
melanoma (71) 71
immunotherapy (64) 64
metastatic melanoma (56) 56
male (49) 49
melanoma - drug therapy (48) 48
female (46) 46
antibodies, monoclonal - therapeutic use (45) 45
cancer (41) 41
middle aged (41) 41
nivolumab (38) 38
aged (36) 36
metastasis (36) 36
treatment outcome (35) 35
care and treatment (34) 34
melanoma - pathology (34) 34
survival (32) 32
adult (31) 31
antibodies, monoclonal - adverse effects (30) 30
antineoplastic agents - therapeutic use (30) 30
open-label (29) 29
safety (28) 28
advanced melanoma (24) 24
chemotherapy (24) 24
skin neoplasms - drug therapy (22) 22
antibodies, monoclonal - administration & dosage (21) 21
pembrolizumab (21) 21
pretreated advanced melanoma (20) 20
adverse events (19) 19
melanoma - mortality (19) 19
neoplasm staging (19) 19
clinical trials (18) 18
retreatment (18) 18
aged, 80 and over (17) 17
efficacy (17) 17
retrospective studies (17) 17
toxicity (17) 17
antineoplastic agents - adverse effects (16) 16
drug therapy (16) 16
neoplasm metastasis (16) 16
patients (16) 16
phase-ii (16) 16
skin neoplasms - pathology (16) 16
cancer therapies (15) 15
medicine & public health (15) 15
young adult (15) 15
analysis (14) 14
cell lung-cancer (14) 14
complications and side effects (14) 14
immunology (14) 14
melanoma - immunology (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
prognosis (13) 13
studies (13) 13
therapy (13) 13
untreated melanoma (13) 13
ctla-4 antigen - immunology (12) 12
ctla-4 blockade (12) 12
double-blind (12) 12
lymphocytes (12) 12
management (12) 12
molecular targeted therapy (12) 12
mutation (12) 12
pd-1 (12) 12
programmed cell death 1 receptor - antagonists & inhibitors (12) 12
research (12) 12
t cells (12) 12
vemurafenib (12) 12
antibody (11) 11
biomarkers (11) 11
clinical trials as topic (11) 11
ctla-4 (11) 11
ctla-4 antigen - antagonists & inhibitors (11) 11
hematology, oncology and palliative medicine (11) 11
immune checkpoint (11) 11
immune system (11) 11
immune-related adverse events (11) 11
medical prognosis (11) 11
medicine, research & experimental (11) 11
melanoma - secondary (11) 11
metastases (11) 11
monoclonal antibodies (11) 11
multicenter (11) 11
tumors (11) 11
antineoplastic agents - administration & dosage (10) 10
cytotoxicity (10) 10
dermatology (10) 10
development and progression (10) 10
immunotherapy - methods (10) 10
medical research (10) 10
melanoma - therapy (10) 10
neoplasms - drug therapy (10) 10
neoplasms - immunology (10) 10
review (10) 10
solid tumors (10) 10
trial (10) 10
antigens (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2698 - 2704
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2019, Volume 30, Issue 4, pp. 582 - 588
Abstract Background Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma.... 
treatment-naive | MULTICENTER | metastatic | EFFICACY | SAFETY | melanoma | pembrolizumab | ONCOLOGY | long-term follow-up | overall survival | PRETREATED ADVANCED MELANOMA | INVESTIGATOR-CHOICE CHEMOTHERAPY | NIVOLUMAB | IPILIMUMAB RETREATMENT | Editor's Choice | Original
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 03/2019, Volume 20, Issue 2, pp. 139 - 141
Immune-checkpoint inhibitors (ICIs) play an important role in treatment for advanced non–small-cell lung cancer. Over one-half of patients, however, have... 
PD-L1 | Clinical trial | Rechallenge | PD-1 | Nivolumab | ONCOLOGY | ADVANCED MELANOMA | IPILIMUMAB RETREATMENT
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 385 - 396
Abstract Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted... 
durable response | SOLID TUMORS | METASTATIC UROTHELIAL CARCINOMA | MONOCLONAL-ANTIBODY | EVALUATION CRITERIA | SINGLE-ARM | CELL CARCINOMA | pseudoprogression | hyperprogression | LUNG-CANCER | treatment beyond progression | ONCOLOGY | immunotherapy | response assessment | PRETREATED ADVANCED MELANOMA | PHASE-III TRIALS | IPILIMUMAB RETREATMENT | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 18, pp. 5349 - 5357
Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2... 
MULTICENTER | ONCOLOGY | 4-1BB | MONOCLONAL-ANTIBODY | OPEN-LABEL | ANTI-CD137 | CLINICAL ACTIVITY | CELL | CARCINOMA | PD-1 | IPILIMUMAB | Neoplasms - metabolism | T-Lymphocyte Subsets - immunology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms - diagnosis | Molecular Targeted Therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | T-Lymphocyte Subsets - drug effects | Aged, 80 and over | Adult | Female | Antibodies, Monoclonal - pharmacokinetics | Neoplasms - mortality | Treatment Outcome | Combined Modality Therapy | Immunoglobulin G - administration & dosage | Neoplasms - drug therapy | Diagnostic Imaging | Retreatment | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | T-Lymphocyte Subsets - metabolism | Tumor Necrosis Factor Receptor Superfamily, Member 9 - antagonists & inhibitors | Aged | Drug Monitoring | Neoplasm Staging | Memory cells | Pharmacodynamics | CD137 antigen | PD-1 protein | Toxicity | CD8 antigen | Immunoglobulin G | Lymphocytes T | Pharmacology | Patients | Anticancer properties | Immunogenicity | Experimental design | Lymphocytes | Safety engineering | Peripheral blood | Monoclonal antibodies | Antitumor activity | Safety | Solid tumors | Pharmacokinetics | Tumors | Cancer | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 45, pp. 73068 - 73079
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2018, Volume 18, Issue 1, pp. 302 - 4
Background: Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients... 
Immune-related adverse events | Immune checkpoint inhibitor | Re-challenge | Nivolumab | Non-small cell lung cancer | METASTATIC MELANOMA | EFFICACY | ONCOLOGY | SAFETY | PRETREATED ADVANCED MELANOMA | DOCETAXEL | IPILIMUMAB RETREATMENT | Lung cancer, Small cell | Development and progression | Chemotherapy | Dru